Application of expression inhibitor of DHX34 gene in preparation of drugs for inhibiting metastasis and invasion of liver cancer cells
A technology of DHX34 and inhibition of liver cancer, applied in the field of biomedicine, can solve the problems of easy metastasis of liver cancer
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
specific Embodiment
[0062] The following will be described in detail in conjunction with specific embodiments. The following examples do not include other components except unavoidable impurities unless otherwise specified. The reagents and instruments used in the examples are all conventional choices in the art unless otherwise specified. The experimental methods for which specific conditions are not indicated in the examples are implemented according to conventional conditions, such as the conditions described in literature, books or the method recommended by the manufacturer. In the following E7107 is:
[0063]
Embodiment 1
[0065] (1) Using CRISPR / Cas9 technology to knock out the DHX34 gene in human liver cancer cell MHCC97H (from Zhongshan Hospital affiliated to Fudan University) to obtain two cell lines MHCC97H-DHX34 KO1 and MHCC97H-DHX34 KO2, and use Western blot to verify DHX34 Knockout of the gene, the results are as follows figure 1 as shown, figure 1"Parantal" refers to the human liver cancer cell MHCC97H group, and the two bands appearing in the human liver cancer cell MHCC97H group are two subunits of DHX34; "DHX34-KO1" refers to the human liver cancer cell MHCC97H-DHX34 KO1 group; "DHX34 -KO2" refers to the MHCC97H-DHX34KO2 group of human liver cancer cells.
[0066] Depend on figure 1 It can be seen that two stable cell lines MHCC97H-DHX34 KO1 and MHCC97H-DHX34 KO2 were successfully constructed by using CRISPR / Cas9 technology to knock out the DHX34 gene.
[0067] (2) Human liver cancer cells MHCC97H, MHCC97H-DHX34 KO1 and MHCC97H-DHX34 KO2 were cultured in DMEM containing 10% fetal ...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


